Blood pressure control is hard to achieve in patients with chronic renal failure: Results from a survey of renal units in Norway

Scandinavian Journal of Urology and Nephrology

Volumn 39, Issue 3, 2005, Pages 242-248

  Prøsch, Line Katrine ^a   Sælen, Marie Grøn ^a   Gudmundsdottir, Helga ^b   Dyrbekk, Dagfinn ^c   Hunderi, Odd Helge ^d   Arnesen, Erik ^e   Paulsen, Dag ^f   Skjønsberg, Helge ^g   Os, Ingrid ^a,b  

^a UNIVERSITY OF OSLO   (Norway)

^b ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^c Vestfold HF   (Norway)

^d Stfold HF   (Norway)

^e Innlandet HF Elverum   (Norway)

^f Innlander HF Lillehammer   (Norway)

^g AKERSHUS UNIVERSITY HOSPITAL   (Norway)

Author keywords

Angiotensin converting enzyme inhibitors; Blood pressure control; Chronic renal failure; Hypertension; Loop diuretics

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LOOP DIURETIC AGENT; METHYLDOPA; MOXONIDINE; THIAZIDE DIURETIC AGENT;

ADULT; AGE; AGED; BLOOD PRESSURE; BLOOD PRESSURE REGULATION; CHRONIC KIDNEY FAILURE; CREATININE BLOOD LEVEL; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NORWAY; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW;

EID: 22144443213     PISSN: 00365599     EISSN: 16512065     Source Type: Journal    
DOI: 10.1080/00365590510007810-1     Document Type: Review

References (35)

1. Peterson JC, Adler S, Burkart JM, Greene T, Hebert LA, Hunsicker LG, et al. Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study. Ann Intern Med 1995; 123:754-62.
2. Bakris GL, Weir MR, Shanifar S, Zhang Z, Douglas J, van Dijk DJ, et al. Effects of blood pressure level on progression of diabetic nephropathy: results from the RENAAL study. Arch Intern Med 2003;163:1555-65.
3. Vikse BE, Aasarod K, Bostad L, Iversen BM. Clinical prognostic factors in biopsy-proven benign nephrosclerosis. Nephrol Dial Transplant 2003;18:517-23.
4. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851-60.
5. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993;329:1456-62.
6. Wright JT Jr, Bakris G, Greene T, Agodoa LY, Appel LJ, Charleston J, et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA 2002;288:2421-31.
7. Agodoa LY, Appel L, Bakris GL, Beck G, Bourgoignie J, Briggs JP, et al. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. JAMA 2001;285:2719-28.
8. Maschio G, Alberti D, Janin G, Locatelli F, Mann JF, Motolese M, et al. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N Engl J Med 1996;334:939-45.
9. Baigent C, Burbury K, Wheeler D. Premature cardiovascular disease in chronic renal failure. Lancet 2000;356:147-52.
10. Ruilope LM, van Veldhuisen DJ, Ritz E, Luscher TF. Renal function: the Cinderella of cardiovascular risk profile. J Am Coll Cardiol 2001;38:1782-7.
11. Rabelink TJ. Cardiovascular risk in patients with renal disease: treating the risk or treating the risk factor? Nephrol Dial Transplant 2004;19:23-6.
12. Law MR, Wald NJ. 2002. Risk factor thresholds: their existence under scrutiny. Br Med J; 324:1570-6
13. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002;39(2 Suppl 1):S1-266.
14. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003;21:1011-53.
15. 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens 2003;21:1983-92.
16. Buckalew VM Jr, Berg RL, Wang SR, Porush JG, Rauch S, Schulman G. Prevalence of hypertension in 1,795 subjects with chronic renal disease: the modification of diet in renal disease study baseline cohort. Modification of Diet in Renal Disease Study Group. Am J Kidney Dis 1990;28:811-21.
17. Ridao N, Luno J, Garcia de Vinuesa S, Gomez F, Tejedor A, Valderrabano F. Prevalence of hypertension in renal disease. Nephrol Dial Transplant 2001;16(Suppl 1):70-3.
18. Coresh J, Wei GL, McQuillan G, Brancati FL, Levey AS, Jones C, et al. Prevalence of high blood pressure and elevated serum creatinine level in the United States: findings from the third National Health and Nutrition Examination Survey (1988-1994). Arch Intern Med ;161 1988;2001:1207-16.
19. Westheim A, Klemetsrud T, Tretli S, Stokke HP, Olsen H. Blood pressure levels in treated hypertensive patients in general practice in Norway. Blood Press 2001;10:37-42.
20. Blacher J, Staessen JA, Girerd X, Gasowski J, Thijs L, Liu L, et al. Pulse pressure not mean pressure determines cardiovascular risk in older hypertensive patients. Arch Intern Med 2000;160:1085-9.
21. Vaccarino V, Berger AK, Abramson J, Black HR, Setaro JF, Davey JA, et al. Pulse pressure and risk of cardiovascular events in the systolic hypertension in the elderly program. Am J Cardiol 2001;88:980-6.
22. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-9.
23. Vasavada N, Agarwal R. Role of excess volume in the pathophysiology of hypertension in chronic kidney disease. Kidney Int 2003;64:1772-9.
24. Nakao N, Yoshimura A, Morita H, Takada M, Kayano T, Ideura T. Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet 2003;361:117-24.
25. Laverman GD, Navis G, Henning RH, de Jong PE, de Zeeuw D. Dual renin-angiotensin system blockade at optimal doses for proteinuria. Kidney Int 2002;62:1020-5.
26. Tylicki L, Rutkowski P, Renke M, Rutkowski B. Renoprotective effect of small doses of losartan and enalapril in patients with primary glomerulonephritis. Short-term observation. Am J Nephrol 2002;22:356-62.
27. Pisoni R, Faraone R, Ruggenent P, Remuzzi G. Inhibitors of the renin-angiotensin system reduce the rate of GFR decline and end-stage renal disease in patients with severe renal insufficiency. J Nephrol 2002;15:428-30.
28. Ruggenenti P, Perna A, Remuzzi G. ACE inhibitors to prevent end-stage renal disease: when to start and why possibly never to stop: a post hoc analysis of the REIN trial results. Ramipril Efficacy in Nephropathy. J Am Soc Nephrol 2001;12:2832-7.
29. Locatelli F, Del Vecchio L, Andrulli S, Colzani S. Role of combination therapy with ACE inhibitors and calcium channel blockers in renal protection. Kidney Int Suppl 2002;82:53-60.
30. Tepel M, Giet MV, Park A, Zidek W. Association of calcium channel blockers and mortality in haemodialysis patients. Clin Sci (Lond) 2002;103:511-5.
31. Kestenbaum B, Gillen DL, Sherrard DJ, Seliger S, Ball A, Stehman-Breen C. Calcium channel blocker use and mortality among patients with end-stage renal disease. Kidney Int 2002;61:2157-64.
32. Orth SR, Amann K, Strojek K, Ritz E. Sympathetic over-activity and arterial hypertension in renal failure. Nephrol Dial Transplant 2001;16(Suppl 1):67-9.
33. Laverman GD, Remuzzi G. Antihypertensive therapy in chronic renal disease: a place for sympathicolytic agents? J Hypertens 2003;21:1625-6.
34. Available from: www.nephro.no/registry/aarsm2002.html
35. Schrier RW, Estacio RO, Esler A, Mehler P. Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney Int 2002;61:1086-97.